Trial Profile
A phase I trial of agalsidase-beta (ISU303) for the treatment of Fabry's-disease
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 27 Apr 2015
Price :
$35
*
At a glance
- Drugs Agalsidase beta (Primary)
- Indications Fabry's disease
- Focus Adverse reactions
- 27 Apr 2015 New trial record